Skip to main content
PMC home page
Neurotherapeutics logoLink to Neurotherapeutics
. 2009 Jan;6(1):78–85. doi: 10.1016/j.nurt.2008.10.020

Building a better antipsychotic: Receptor targets for the treatment of multiple symptom dimensions of schizophrenia

Dennis H Kim 1, Matthew J Maneen 1, Stephen M Stahl 2,✉
PMCID: PMC5084257  PMID: 19110200

Summary

Attempts to develop selective (“magic bullet”) drugs for the treatment of schizophrenia have been frustrated by the complex etiology of the disease. The symptomatology of schizophrenia does not appear to arise from a single neurobiological entity, but rather may be derived from pathology at one or more receptor types. This has prompted multifactorial approaches to the development of new therapeutics, as embodied by polypharmacy and an alternative (or augmentative) strategy known as ldintramolecular polypharmacy,” in which a single drug possesses the capacity to affect multiple receptor types. Atypical antipsychotics are a well-known example of this approach; each atypical possesses a unique portfolio of activities at receptors that may contribute to therapeutic effects (as well as side effects). In this article we present a discussion of some of the receptor targets that are currently thought to mediate symptoms of schizophrenia, as well as their possible implications for the design of future multifunctional antipsychotics.

Key Words: Antipsychotics, intramolecular polypharmacy, receptors, negative symptoms, glutamatergic neurotransmission

References

  • 1.Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32:214–219. doi: 10.1093/schbul/sbj053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Stahl SM. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications. 3rd ed. New York: Cambridge University Press; 2008. [Google Scholar]
  • 3.Strange PG. Antipsychotic drug action: antagonism, inverse agonism or partial agonism. Trends Pharmacol Sci. 2008;29:314–321. doi: 10.1016/j.tips.2008.03.009. [DOI] [PubMed] [Google Scholar]
  • 4.Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry. 2001;158:360–369. doi: 10.1176/appi.ajp.158.3.360. [DOI] [PubMed] [Google Scholar]
  • 5.Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10:79–104. doi: 10.1038/sj.mp.4001556. [DOI] [PubMed] [Google Scholar]
  • 6.Meltzer HY. What’s atypical about atypical antipsychotic drugs? Curr Opin Pharmacol. 2004;4:53–57. doi: 10.1016/j.coph.2003.09.010. [DOI] [PubMed] [Google Scholar]
  • 7.Schmidt AW, Lebel LA, Howard HR, Zom SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425:197–201. doi: 10.1016/S0014-2999(01)01188-8. [DOI] [PubMed] [Google Scholar]
  • 8.Stahl SM. Do dopamine partial agonists have partial efficacy as antipsychotics? CNS Spectr. 2008;13:279–282. doi: 10.1017/s1092852900016382. [DOI] [PubMed] [Google Scholar]
  • 9.Bums KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302:381–389. doi: 10.1124/jpet.102.033175. [DOI] [PubMed] [Google Scholar]
  • 10.Calsson A, Waters N, Carlsson ML. Neurotransmitter interactions in schizophrenia—therapeutic implications. Biol Psychiatry. 1999;46:1388–1395. doi: 10.1016/S0006-3223(99)00117-1. [DOI] [PubMed] [Google Scholar]
  • 11.Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999;20:612–627. doi: 10.1016/S0893-133X(98)00099-2. [DOI] [PubMed] [Google Scholar]
  • 12.Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S. Differential effects of aripiprazole on D2, 5-HT2, and 5-HT1A receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry. 2007;164:1411–1417. doi: 10.1176/appi.ajp.2007.06091479. [DOI] [PubMed] [Google Scholar]
  • 13.Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68:843–853. doi: 10.4088/JCP.v68n0604. [DOI] [PubMed] [Google Scholar]
  • 14.Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. 2008;28:13–20. doi: 10.1097/jcp.0b013e3181618eb4. [DOI] [PubMed] [Google Scholar]
  • 15.Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O’Laughlin IA, Meltzer HY. 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem. 2001;76:1521–1531. doi: 10.1046/j.1471-4159.2001.00154.x. [DOI] [PubMed] [Google Scholar]
  • 16.Azmitia EC, Gannon PJ, Kheck NM, Whitaker-Azmitia PM. Cellular localization of the 5-HT1A receptor in primate brain neurons and glial cells. Neuropsychopharmacology. 1996;14:35–46. doi: 10.1016/S0893-133X(96)80057-1. [DOI] [PubMed] [Google Scholar]
  • 17.Sumiyoshi T, Matsui M, Nohara S, et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry. 2001;158:1722–1725. doi: 10.1176/appi.ajp.158.10.1722. [DOI] [PubMed] [Google Scholar]
  • 18.Yasuno F, Suhara T, Nakayama T, et al. Inhibitory effect of hippocampal 5-HT1A receptors on human explicit memory. Am J Psychiatry. 2003;160:334–340. doi: 10.1176/appi.ajp.160.2.334. [DOI] [PubMed] [Google Scholar]
  • 19.Gray JA, Roth BL. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull. 2007;33:1100–1119. doi: 10.1093/schbul/sbm074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther. 2007;113:296–320. doi: 10.1016/j.pharmthera.2006.08.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Millan MJ, Dekeyne A, Gobert A. Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology. 1998;37:953–955. doi: 10.1016/S0028-3908(98)00078-1. [DOI] [PubMed] [Google Scholar]
  • 22.Gray JA, Roth BL. The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007;12:904–922. doi: 10.1038/sj.mp.4002062. [DOI] [PubMed] [Google Scholar]
  • 23.Alex KD, Yavanian GJ, McFarlane HG, Pluto CP, Pehek EA. Modulation of dopamine release by striatal 5-HT2C receptors. Synapse. 2005;55:242–251. doi: 10.1002/syn.20109. [DOI] [PubMed] [Google Scholar]
  • 24.Gunes A, Dahl ML, Spina E, Scordo MG. Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. Eur J Clin Pharmacol. 2008;64:477–482. doi: 10.1007/s00228-007-0450-x. [DOI] [PubMed] [Google Scholar]
  • 25.Reavill C, Kettle A, Holland V, Riley G, Blackburn TP. Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol. 1999;126:572–574. doi: 10.1038/sj.bjp.0702350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Stahl SM. Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. Int J Neuropsychopharmacol. 2007;10:575–578. doi: 10.1017/S1461145707008000. [DOI] [PubMed] [Google Scholar]
  • 27.Bard JA, Zgombick J, Adham N, Vaysse P, Branchek TA, Weinshank RL. Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. J Biol Chem. 1993;268:23422–23426. [PubMed] [Google Scholar]
  • 28.Lovenberg TW, Baron BM, de LL, et al. A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. Neuron. 1993;11:449–458. doi: 10.1016/0896-6273(93)90149-L. [DOI] [PubMed] [Google Scholar]
  • 29.Ruat M, Traiffort E, Leurs R, et al. Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation. Proc Natl Acad Sci USA. 1993;90:8547–8551. doi: 10.1073/pnas.90.18.8547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Mullins UL, Gianutsos G, Eison AS. Effects of antidepressants on 5-HT7 receptor regulation in the rat hypothalamus. Neuropsychopharmacology. 1999;21:352–367. doi: 10.1016/S0893-133X(99)00041-X. [DOI] [PubMed] [Google Scholar]
  • 31.Roth BL, Craigo SC, Choudhary MS, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994;268:1403–1410. [PubMed] [Google Scholar]
  • 32.Thomas DR, Melotto S, Massagrande M, et al. SB-656104-A, a novel selective 5-HT7 receptor antagonist, modulates REM sleep in rats. Br J Pharmacol. 2003;139:705–714. doi: 10.1038/sj.bjp.0705290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Guscott MR, Egan E, Cook GP, et al. The hypothermic effect of 5-CT in mice is mediated through the 5-HT7 receptor. Neuropharmacology. 2003;44:1031–1037. doi: 10.1016/S0028-3908(03)00117-5. [DOI] [PubMed] [Google Scholar]
  • 34.Hagan JJ, Rice GW, Jeffrey P, et al. Characterization of SB-269970-A, a selective 5-HT7 receptor antagonist. Br J Pharmacol. 2000;130:539–548. doi: 10.1038/sj.bjp.0703357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Hedlund PB, Danielson PE, Thomas EA, Slanina K, Carson MJ, Sutcliffe JG. No hypothermic response to serotonin in 5-HT7 receptor knockout mice. Proc Natl Acad Sci USA. 2003;100:1375–1380. doi: 10.1073/pnas.0337340100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Manuel-Apolinar L, Meneses A. 8-OH-DPAT facilitated memory consolidation and increased hippocampal and cortical cAMP production. Behav Brain Res. 2004;148:179–184. doi: 10.1016/S0166-4328(03)00186-4. [DOI] [PubMed] [Google Scholar]
  • 37.Roberts AJ, Krucker T, Levy CL, Slanina KA, Sutcliffe JG, Hedlund PB. Mice lacking 5-HT7 receptors show specific impairments in contextual learning. Eur J Neurosci. 2004;19:1913–1922. doi: 10.1111/j.1460-9568.2004.03288.x. [DOI] [PubMed] [Google Scholar]
  • 38.Jorgensen H, Riis M, Knigge U, Kjaer A, Warberg J. Serotonin receptors involved in vasopressin and oxytocin secretion. J Neuroendocrinol. 2003;15:242–249. doi: 10.1046/j.1365-2826.2003.00978.x. [DOI] [PubMed] [Google Scholar]
  • 39.Laplante P, Diorio J, Meaney MJ. Serotonin regulates hippocampal glucocorticoid receptor expression via a 5-HT7 receptor. Brain Res Dev Brain Res. 2002;139:199–203. doi: 10.1016/S0165-3806(02)00550-3. [DOI] [PubMed] [Google Scholar]
  • 40.Stahl SM. Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia. CNS Spectr. 2007;12:265–268. doi: 10.1017/s1092852900021015. [DOI] [PubMed] [Google Scholar]
  • 41.Newcomer JW, Farber NB, Jevtovic-Todorovic V, et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology. 1999;20:106–118. doi: 10.1016/S0893-133X(98)00067-0. [DOI] [PubMed] [Google Scholar]
  • 42.Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res. 1999;33:523–533. doi: 10.1016/S0022-3956(99)00029-1. [DOI] [PubMed] [Google Scholar]
  • 43.Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 1998;281:1349–1352. doi: 10.1126/science.281.5381.1349. [DOI] [PubMed] [Google Scholar]
  • 44.Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry. 2004;9:984–997. doi: 10.1038/sj.mp.4001551. [DOI] [PubMed] [Google Scholar]
  • 45.Johnson JW, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature. 1987;325:529–531. doi: 10.1038/325529a0. [DOI] [PubMed] [Google Scholar]
  • 46.Mothet JP, Parent AT, Wolosker H, et al. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA. 2000;97:4926–4931. doi: 10.1073/pnas.97.9.4926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Goff DC, Herz L, Posever T, et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl) 2005;179:144–150. doi: 10.1007/s00213-004-2032-2. [DOI] [PubMed] [Google Scholar]
  • 48.Heresco-Levy U, Javitt DC. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res. 2004;66:89–96. doi: 10.1016/S0920-9964(03)00129-4. [DOI] [PubMed] [Google Scholar]
  • 49.Tsai GE, Yang P, Chang YC, Chong MY. D-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2006;59:230–234. doi: 10.1016/j.biopsych.2005.06.032. [DOI] [PubMed] [Google Scholar]
  • 50.Javitt DC. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Curr Opin Psychiatry. 2006;19:151–157. doi: 10.1097/01.yco.0000214340.14131.bd. [DOI] [PubMed] [Google Scholar]
  • 51.van Berckel BN, Evenblij CN, van Loon BJ, et al. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology. 1999;21:203–210. doi: 10.1016/S0893-133X(99)00014-7. [DOI] [PubMed] [Google Scholar]
  • 52.Bergeron R, Meyer TM, Coyle JT, Greene RW. Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci USA. 1998;95:15730–15734. doi: 10.1073/pnas.95.26.15730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Stahl SM. Novel therapeutics for schizophrenia: targeting glycine modulation of NMDA glutamate receptors. CNS Spectr. 2007;12:423–427. doi: 10.1017/s1092852900015297. [DOI] [PubMed] [Google Scholar]
  • 54.Burstein ES, Ma J, Wong S, et al. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther. 2005;315:1278–1287. doi: 10.1124/jpet.105.092155. [DOI] [PubMed] [Google Scholar]
  • 55.Sur C, Mallorga PJ, Wittmann M, et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA. 2003;100:13674–13679. doi: 10.1073/pnas.1835612100. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES